CSL's new CEO confirms focus on growth

Mr Paul Perreault isn't planning on taking his foot off the accelerator.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Specialty biopharmaceutical company CSL's (ASX: CSL) newly installed Chief Executive Officer Mr Paul Perreault has said in an interview with Business Spectator that he will not be stopping the aggressive growth that was a hallmark of his predecessor's tenure.

While new CEOs taking about aggressive growth could often be a warning sign for investors, in this case investors can take solace from Mr Perreault's view that there is significant opportunity to optimise what CSL already has rather than using risky acquisitions to achieve growth. In fact Mr Perreault pleasingly appears to have a sound understanding of the risks of acquisition as this comment during the interview shows: "think about when people do acquisitions, look at how and why they do acquisitions. It's usually done from a position of weakness, not from a position of strength."

Shareholders will be exciting to learn just how many developed products CSL already has that for one reason or another are being marketed in one region (for example Germany) but are not yet marketed in other regions (for example the USA). This pipeline alone has the potential to provide significant and sustaining growth in sales to CSL for quite some time.

In many ways CSL has a 'double play' that peers such as Cochlear (ASX: COH) and ResMed (ASX: RMD) don't have. Not only can CSL expand into new geographies (as can Cochlear and ResMed) but it can also significantly expand sales of its diverse product pipeline as well.

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

More reading


Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »